Sept. 13, 2019
Seeking to improve outcomes for patients undergoing autologous stem cell transplantation
Platelet transfusions have been part of routine supportive care for patients with hematologic malignancies since the 1960s. Current standard of practice is to transfuse platelets prophylactically to prevent bleeding when the platelet count is very low (less than 10 x 10^9/L). However, recent studies suggest that this practice may not reduce bleeding in patients undergoing autologous stem cell transplantion.
Dr. Tay and colleagues have successfully undertaken a pilot study to evaluate a trial comparing prophylactic tranexamic acid (a drug that reduces bleeding by preventing the break down of blood clots) to prophylactic platelet transfusions in patients undergoing an autologous stem cell transplantation. They will now undertake a large study to determine if prophylactic tranexamic acid as compared to prophylactic platelet transfusions will reduce the amount of serious bleeding in patients undergoing an autologous stem cell transplant. A total of 662 patients will be enrolled at 9 Canadian transplant centres over the next 5 years. Patients will be randomly assigned to either prophylactic tranexamic acid or prophylactic platelet transfusions during the period immediately following the stem cell transplant. All patients can receive additional platelet transfusions to treat bleeding episodes. All patients will be followed daily for 6 months following their stem cell transplant. They will be monitored daily for bleeding daily using a standardized bleeding assessment until their platelet counts recover. They will also be followed for quality of life measureents (4 weeks) and any adverse events (6 months).
This study is funded by the Canadian Institutes of Health Research through the Spring 2019 Project Grant competition.